Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/clavulanic acid extra strength - GSK

Next Previous
Drug Profile

Amoxicillin/clavulanic acid extra strength - GSK

Alternative Names: Augmentin (ES)-600; Augmentin ES; Augmentin ES Chewable; Augmentin ES-600; Augmentin Extra Strength - GSK; Dry syrup formulation of Augmentin ES; Extra strength amoxicillin/clavulanate potassium - GSK; Extra-strength amoxicillin/clavulanic acid

Latest Information Update: 10 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class 2 ring heterocyclic compounds; Antibacterials; Azetidines; Beta-lactams; Carboxylic acids; Oxazolidinones; Penicillins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis media
  • Discontinued Rhinosinusitis

Most Recent Events

  • 22 Apr 2022 GlaxoSmithKline plans a phase II trial for community acquired pneumonia (CAP) and acute bacterial rhinosinusitis (ABRS) (In Children) in Brazil in 2022 (NCT05340257)
  • 22 Dec 2020 Chemical structure information added
  • 23 Oct 2020 Launched for Otitis media in India before October 2020 (PO) (NCT04600752)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top